Myeloid-biased HSC require Semaphorin 4A from the bone marrow niche for self-renewal under stress and life-long persistence

Dorsa Toghani(Fred Hutch Cancer Center), Lev Silberstein(Massachusetts General Hospital), Edie I. Crosse(MRC Centre for Regenerative Medicine), David M. Gravano(University of California, Merced), Atsushi Kumanogoh(The University of Osaka), Amogh Pradeep(Fred Hutch Cancer Center), Eric M. Pietras(University of Colorado Anschutz Medical Campus), Peter V. Kharchenko(Fleet Science Center), Sarah Kinston(University of Cambridge), Claus Nerlov(John Radcliffe Hospital), Stefan Radtke(Fred Hutch Cancer Center), Sónia Rodríguez(City of Hope), Marion Mesnieres(KU Leuven), Hans‐Peter Kiem(Fred Hutch Cancer Center), Joel A. Spencer(Massachusetts General Hospital), Negar Seyedhassantehrani(University of California, Merced), Christian Burns(University of California, Merced), Christa Maes(KU Leuven), Antonio Scialdone(Helmholtz Zentrum München), Nadia Carlesso(City Of Hope National Medical Center), Thomas Worzfeld(Philipps University of Marburg), David T. Scadden(Harvard University), Elmir Mahammadov(Helmholtz Munich), Sharon Zeng(Fred Hutch Cancer Center), Nicola K. Wilson(University of Cambridge), Berthold Göttgens(Wellcome/MRC Cambridge Stem Cell Institute)
bioRxiv (Cold Spring Harbor Laboratory)
January 12, 2022
Cited by 1


Related Papers